You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

How does GSK calculate your local budget impact?

How do GSK’s respiratory budget impact models work?

  • Our budget impact models can help you to estimate the potential cost savings available in your locality from using GSK’s Ellipta portfolio of respiratory medicines.
  • We use local prescribing data from Health & Social Care Information Centre (HSCIC) and combine this with other data sources. These potential cost savings are dependent on your local data and inputs agreed in collaboration with a Health Outcomes Consultant (HOC).
  • This information may help inform local formulary decisions, guidelines development, and highlight areas of focus for medicines optimisation programmes.

What data sources are used in our respiratory models?

1. National patient level data from GP databases are used to add real world insight into the budget impact models, including:

  • Differentiating between asthma and COPD patients
  • The proportions of COPD patients who experience an exacerbation or symptoms of breathlessness.

2. Local sales information is obtained from practice prescribing data (PPD).

Is the data used to calculate my respiratory budget impact relevant to me?

  • The models are dynamic, and any assumptions applied can be altered in collaboration with your HOC to ensure that the budget impact figure calculated is reflective of your prescribing habits and local knowledge.

Does the model require patients to be switched to achieve savings?

Prior to a change of therapy, GSK advocates that all patients should have a clinical review to optimise their treatment, which may include a simplification of device and/or dosing regimen.

Do you have any further questions?

If you would like more information, or to discuss potential cost savings available in your locality from using GSK’s Ellipta portfolio of respiratory medicines, please contact us via the ‘HOC: on-Demand’.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

Relvar, Anoro, Incruse and Ellipta are registered trademarks of the GlaxoSmithKline group of companies